ResMed (RMD - Free Report) reported $1.12 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 22.7%. EPS of $1.60 for the same period compares to $1.49 a year ago.
The reported revenue represents a surprise of +0.36% over the Zacks Consensus Estimate of $1.12 billion. With the consensus EPS estimate being $1.67, the EPS surprise was -4.19%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- U.S., Canada, and Latin America- Devices: $387.20 million versus $385.02 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +29.5% change.
- U.S., Canada, and Latin America- Masks: $273.70 million versus the four-analyst average estimate of $257.20 million. The reported number represents a year-over-year change of +19.2%.
- Combined Europe, Asia, and other markets- Total Sleep and Respiratory Care: $322.60 million versus the four-analyst average estimate of $338.02 million. The reported number represents a year-over-year change of +14%.
- Combined Europe, Asia, and other markets- Devices: $215.20 million versus $228.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +14.4% change.
- Combined Europe, Asia, and other markets- Masks: $107.40 million versus the four-analyst average estimate of $109.93 million. The reported number represents a year-over-year change of +13.2%.
- U.S., Canada, and Latin America- Total: $660.90 million compared to the $664.45 million average estimate based on three analysts.
- Global revenue- Total Sleep and Respiratory Care: $983.50 million versus the five-analyst average estimate of $980.58 million. The reported number represents a year-over-year change of +21.2%.
- Global revenue- Software as a Service: $138.60 million versus the four-analyst average estimate of $139.17 million. The reported number represents a year-over-year change of +34.4%.
- Global revenue- Devices: $602.40 million compared to the $629.87 million average estimate based on four analysts. The reported number represents a change of +23.7% year over year.
- Global revenue- Masks: $381 million versus $374.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +17.5% change.
View all Key Company Metrics for ResMed here>>>Shares of ResMed have returned +2.6% over the past month versus the Zacks S&P 500 composite's +1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
ResMed (RMD - Free Report) reported $1.12 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 22.7%. EPS of $1.60 for the same period compares to $1.49 a year ago.
The reported revenue represents a surprise of +0.36% over the Zacks Consensus Estimate of $1.12 billion. With the consensus EPS estimate being $1.67, the EPS surprise was -4.19%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- U.S., Canada, and Latin America- Devices: $387.20 million versus $385.02 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +29.5% change.
- U.S., Canada, and Latin America- Masks: $273.70 million versus the four-analyst average estimate of $257.20 million. The reported number represents a year-over-year change of +19.2%.
- Combined Europe, Asia, and other markets- Total Sleep and Respiratory Care: $322.60 million versus the four-analyst average estimate of $338.02 million. The reported number represents a year-over-year change of +14%.
- Combined Europe, Asia, and other markets- Devices: $215.20 million versus $228.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +14.4% change.
- Combined Europe, Asia, and other markets- Masks: $107.40 million versus the four-analyst average estimate of $109.93 million. The reported number represents a year-over-year change of +13.2%.
- U.S., Canada, and Latin America- Total: $660.90 million compared to the $664.45 million average estimate based on three analysts.
- Global revenue- Total Sleep and Respiratory Care: $983.50 million versus the five-analyst average estimate of $980.58 million. The reported number represents a year-over-year change of +21.2%.
- Global revenue- Software as a Service: $138.60 million versus the four-analyst average estimate of $139.17 million. The reported number represents a year-over-year change of +34.4%.
- Global revenue- Devices: $602.40 million compared to the $629.87 million average estimate based on four analysts. The reported number represents a change of +23.7% year over year.
- Global revenue- Masks: $381 million versus $374.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +17.5% change.
View all Key Company Metrics for ResMed here>>>Shares of ResMed have returned +2.6% over the past month versus the Zacks S&P 500 composite's +1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on RMD - FREE